Safety and efficacy of transdermal buprenorphine for the relief of cancer pain
This study aimed to synthesize the available evidence on the efficacy and safety of transdermal (TD) buprenorphine.
We searched studies in electronic databases. Randomized controlled trials (RCTs) assessing the efficacy of TD buprenorphine comparing with placebo or other comparator drug in relieving cancer pain were included. The primary end points are patient-reported pain intensity and pain relief. For dichotomous data, the summary relative risk (RR) and its 95 % confidence interval (CI) were derived using random-effect model in view of heterogeneity testing.
Eight clinical trials (n = 909) were included in the analysis. Only a few studies reported the same outcome in similar way, which created difficulty in the pooling of outcome data. Two studies (n = 288) assessed ‘responders’ and showed a significant difference between TD buprenorphine and placebo in all three doses of TD buprenorphine, 35.5, 52.5, or 70 μg/h (RR 1.74, 95 % CI 1.31–2.32; I2 0 %); the numbers-needed-to-treat was 5.8 (3.9–11). Two studies (n = 331) showed a comparable requirement for rescue SL buprenorphine between TD buprenorphine and placebo (RR 1.25, 95 % CI 0.84–1.88; I2 0 %). The preferred outcome measure ‘50 % pain relief’ was not reported in any included studies. On the basis of summary quality, further research is likely to have an important impact on our confidence in the estimate.
Transdermal buprenorphine has an increasing role for the relief of cancer pain. Further research in this field is needed. Multicentre studies in this field using a common protocol and strict supervision will be more practicable.
KeywordsBuprenorphine Transdermal Cancer Pain
- Aurilio C, Pace MC, Pota V, Sansone P, Barbarisi M, Grella E, Passavanti MB et al (2009) Opioids switching with transdermal systems in chronic cancer pain. J Exp Clin Cancer Res 28(61) Google Scholar
- Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383–394Google Scholar
- Hanks GW, Kaasa S, Mercadante S, Olarte JMN, Poulain P, Radbruch L (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Expert working group of the research network of the European association for palliative care. Br J Cancer 84((5):587–593CrossRefPubMedCentralPubMedGoogle Scholar
- Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org
- IASP (International Associations of Pain) (2010) Proceedings of the Congress of the European Federation of IASP. In: http://www.iasp-pain.org
- Lutfy K, Cowan A (2004) Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2(4):395–402Google Scholar
- Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G et al (2008) Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 8(4):287–313CrossRefPubMedGoogle Scholar
- Quigley C (2004) Opioid switching to improve pain relief and drug tolerability. Cochrane Database of Systematic Reviews Issue 3. Art. No.: CD004847. doi:10.1002/14651858.CD004847
- Sittl R, Griessinger N, Likar R (2003) Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomised, double-blind, placebo controlled trial. Clin Ther 25:150–168CrossRefPubMedGoogle Scholar
- Skaer TL (2006) Transdermal opioids for cancer pain. Health Qual Life Outcomes 4(24)Google Scholar
- WHO (World Health Organization) (1996) Cancer pain relief, 2nd edn. World Health Organization, GenevaGoogle Scholar
- WHO (World Health Organization) (2000) Narcotic and psychotropic drugs achieving balance in national opioids control policy: guidelines for assessment. WHO [Other: WHO/EDM/QSM/2000.4]Google Scholar
- WHO (World Health Organization) (2009) WHO guidelines: cancer control. WHO, GenevaGoogle Scholar
- Wolff RF, Aune D, Truyers C, Hernandez AV, Misso K, Riemsma R et al (2012) Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. CMRO 28:833–845Google Scholar
- Yaksh TL, Wallace MS (2011). Ch 18. Opioids, analgesia, and pain management: introduction. In: Brunton LL, Chabner BA, Knollmann BC (eds) Goodman & Gilman’s the pharmacological basis of therapeutics. 12th edn. The McGraw-Hill Companies, [http://www.accessmedicine.com/content.aspx?aID=16663974]